• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Dendreon Corp

+ Add to Watchlist

DNDN:US

1.5000 USD 0.0800 5.63%

As of 20:10:00 ET on 09/19/2014.

Snapshot for Dendreon Corp (DNDN)

Open: 1.4600 Day's Range: 1.3800 - 1.5900 Volume: 11,993,714
Previous Close: 1.4200 52wk Range: 1.2400 - 3.5200 1-Yr Rtn: -50.82%

Stock Chart for DNDN

No chart data available.
  • DNDN:US 1.4900
  • 1D
  • 1M
  • 1Y
1.4200
Interactive DNDN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DNDN

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.1101
Est. EPS (USD) (12/2014) -0.7270
Est. PEG Ratio -
Market Cap (M USD) 240.47
Shares Outstanding (M) 160.31
30 Day Average Volume 3,083,593
Price/Book (mrq) -
Price/Sale (ttm) 0.7816
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/12/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DNDN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DNDN

Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company combines knowledge in immunology and antigen engineering with proprietary cell separation technologies to develop therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer.

Douglas G Watson "Doug"ChairmanW Thomas Amick "Tom"President/CEO
Andrew S SandlerExec VP/Chief Medical OfficerGregory R CoxInterim CFO/VP:Finance
More Company Profile & Key Executives for DNDN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil